Background: We report the first study examining the clinical, numerical and biological properties of circulating tumor cells according to molecular subtypes of non-small-cell lung cancer.
Introduction
Circulating tumor cells (CTCs) represent an alternative source of tumor tissue which are accessible using a simple blood test. Their use has the potential to allow longitudinal monitoring of tumor biology at different timepoints, guiding therapeutic decisions according to resistance in a patient's treatment course [1] . In non-small cell lung cancer (NSCLC), their optimization is particularly relevant given that an increasing demand for sequencing of multiple genes in 'umbrella' clinical trials does not yet square with the technical difficulties and small tissue samples involved with pulmonary biopsy in many patients [2] .
To date the CellSearch V R technology remains the only FDAapproved CTC-isolation system proven to have both assay and clinical/biological validity in cancer: using this platform, CTCs are isolated using immunomagnetic enrichment for the epithelial cell adhesion molecule (EPCAM) [3] . Two key reports have investigated CTC enumeration in NSCLC using CellSearch. An initial proof-of-principle that CTC identification and enumeration was possible in lung cancer was followed by a report offering information on the benefits and limitations of CellSearch quantification in NSCLC: 21% of 109 treatment-naïve stage III/IV patients had positive CTC counts at baseline (defined as !2 CTCs in 7.5 ml blood since 1 CTC is a normal finding in healthy controls), while hypothesis-generating information on the prognostic capacity of CTC enumeration (cutoff !5 CTCs, 8Á3% of patients) was also described [3, 4] . Other clinical reports have described a role for baseline prognostication using CellSearch in NSCLC, although with small patient numbers and no validation set [5] [6] [7] [8] .
Vimentin is a filamental protein expressed in mesenchymal cells, often recorded as a marker of tumor cell invasion via its expression during aberrant activation of the epithelial-mesenchymal transition (EMT). EMT is a biological program in which a series of dynamic and transitional steps can transform an epithelial cancer cell towards a more mesenchymal phenotype. EMT cells and their intermediate states have been associated with various tumorigenic properties including chemoresistance, tumor progression, and stem cell character [9] . Its representation in CTCs has been demonstrated on a number of occasions using various CTC isolation platforms, with ours and other groups reporting the existence of CTCs undergoing EMT in NSCLC using filtration-enrichment [10] [11] [12] [13] [14] . 'Previously we also demonstrated that isolation of vimþ CTCs in castrate-resistant prostate cancer conferred poorer survival [15, 16] .
Here we examined three areas of clinical and translational significance for development of CTCs in NSCLC. First, we explored the total number of CTCs as a prognostic marker in treatmentnaive advanced NSCLC, acting as a validation for the previously estimated prognostic cutoff of !5 total CTCs. Second, we explored the prognostic value of vim þ CTCs in total CTCþ patients, assessing in turn their dynamic change with treatment. Finally, we correlated total CTC and vim þ CTC profiles with somatic alterations of EGFR, ALK and KRAS.
Methods

Study design
CTC analyses were performed on 154 patients with presumed advanced (stage IIIb-IV) systemic treatment-naïve NSCLC who were prospectively included into one of two Gustave-Roussy translational sample collection protocols, MSN (145 patients, 2008-A00373-52) and CEC-CTC (9 patients, IDRCB2008-AOO585-50), between September 2010 and June 2015. Patients signed informed consent to undergo a peripheral blood sample: one CellSave tube at most 7 days prior to chemotherapy. The MSN and CEC-CTC protocols were approved by the local Gustave Roussy ethics review committee.
For eligibility, patients could be diagnosed either by contemporaneous or historical biopsy, and were excluded if they were suffering from a second malignancy. Routine laboratory analyses were also performed on all patients, with data prospectively collected for age, sex, histological subtype, genotype, ECOG performance status, smoking status, sites of metastasis, treatment received, previous adjuvant treatment, stage, date of progression, date of death, date of inclusion for CellSearch analysis, CellSearch results, and date of last follow-up.
Routine analyses of patient tumor biopsies for ALK rearrangement, KRAS mutation, and EGFR mutation were performed as previously described for the French molecular testing network [17] . Given their mutual exclusivity, patients whose cancers featured genetic modification of KRAS were assumed to be wild-type for EGFR and ALK in the minority of cases where these modifications had not been tested; this approach was also used in the case of cancers with EGFR mutation and ALK rearrangement.
CTC analysis
Collection of blood, immunomagnetic selection, and immunofluorescent staining of CTCs were performed using the CellSearch V R system (Janssen Diagnostics), as previously reported [18] . Blood samples were collected and stored at room temperature in 10 ml CellSave (Janssen Diagnostics, LLC) preservative tubes, then processed within 72 h of collection. FITC-labeled anti-vimentin antibody (Santa-Cruz) was added to the free channel of the CellSearch platform, as has been described previously [15] . Candidate total CTCs and vimþ CTCs were identified using the CellTracks Analyzer II (Janssen Diagnostics, LLC). In line with previous literature showing 1 CTC could be a normal finding in healthy controls, total CTCþ was defined as !2 total CTCs, and vim CTCþ was a patient who had !1 vimentin expressing CTC and known to be total CTCþ overall (i.e. !2 total CTCs, of which !1 expressed vimentin) [3, 4] . The unfavorable prognostic CTC category was defined as !5 total CTCs [4] .
Statistical analysis
REMARK guidelines were followed in planning, analysis and reporting of the study. The association of total and vimþ CTC number with clinical characteristics and patient demographics was assessed using Fisher's exact test for dichotomous factors, and Mann-Whitney tests for continuous data. For survival analysis, baseline CTC values and standard clinical factors including age, performance status (PS), histology, and smoking status were considered for multivariate analysis of both progression-free survival (PFS) and overall survival (OS). Factors that were significant in univariate analysis were included in multivariate Cox proportional hazards regression analysis (forward stepwise selection method with P 0.2 selected for entry into the model). The Kaplan-Meier method was used to estimate PFS and OS, and the survival distribution according to CTC values compared using the log-rank test and Cox regression. OS was defined as the time from inclusion for first CTC sample until death from any cause, cancer-related or otherwise. PFS was defined as the time from inclusion for first CTC sample until tumor progression or death, whichever came first. If no event had occurred, patients were censored at date of last follow-up. P values were two-sided and considered statistically significant at <0.05. Statistical analysis was performed using SPSS version 23 and GraphPad Prism 6.03 for Windows.
Results
Patient characteristics
CTC runs were initially performed in 154 treatment-naive lung cancer patients, of which 29 were subsequently excluded from analysis (eight with small cell lung cancer, 21 with stage I-IIIa NSCLC). Three patients were lost to follow-up and censored at their last appointment ( Figure 1 ). A total of 125 advanced treatment-naïve NSCLC patients (stage IIIb-IV) were included for final analysis: 74 patients were total CTC-negative at baseline and 51 patients were total CTCþ. Patient recruitment and baseline clinical details are recorded in Table 1 and Figure 1 . A higher proportion of poor performance status was noted in those patients who were total CTCþ (P ¼ 0.003) ( Table 1) . Otherwise there were no significant differences between the groups in terms of histology, smoking, or metastatic burden. A baseline analysis of patient overall survival according to EGFR, ALK, and KRAS subgroups was consistent with what has been described previously for each subgroup (supplementary Figure S1 , available at Annals of Oncology online).
For baseline CTC characteristics, !1 total CTC(s) was present in the samples of 54.4% of patients, !2 total CTCs in 40.8% of patients, and !5 total CTCs in 19.2% ( Table 2 ). The number of total CTCs ranged from 0 to 78 across all 125 patients, although the majority of total CTCþ patients displayed counts of between 2 and 10 total CTCs (Table 2) . For vimþ CTCs, !1 vimþ CTC(s) was seen in 23.3% of patients, !2 vimþ CTCs in 14.4% of patients, and !5 vimþ CTCs in 5.6%. Range of vimþ CTCs was 0-35, with the majority of positive cases being in the very low end of this range ( Table 2) . 8/125 patients (6.4%) harbored vimþ CTCs exclusively. In total, 140/873 (16%) of CTCs were vimþ across baseline samples from the cohort ( Table 2) .
Clinical relevance of total CTCs
After a median follow-up of 47 months, univariate analyses showed significant reductions in median PFS/OS were evident in patients with !5 total CTCs at baseline compared to those with <5 total CTCs (PFS: 147 vs 173 days and 6 month PFS 29.2% vs 45.1%, respectively; HR 0.59, 95% CI 0.37-0.94, P ¼ 0.026; OS: median 197 vs 386 days and 1 year OS 22.9% vs 56%, respectively; HR 0.45, 95% CI 0.28-0.75, P ¼ 0.002) ( Figure  2A and B). Multivariate analysis confirmed that !5 total CTCs was an independent prognostic indicator for OS (HR 0.55, 95% CI 0.33-0.92, P ¼ 0.022) but not PFS (HR 0.68, 95% CI 0.42-1.1, P ¼ 0.118).
Clinical relevance of vimentin-positive CTCs
We next sought to describe and establish the prognostic significance of baseline vimþ CTCs (supplementary Figure S2, Figure 3A and B). As EMT has been associated with treatment resistance in CTCs, we hypothesized that the vimþ profile of CTCs may develop during treatment, even if overall CTC numbers were to diminish. 75 patients (60%) in our cohort offered a second 'ontreatment' sample for CellSearch analysis: 65 after cycle 1 and 10 after cycle 2. No difference was observed between baseline and paired on-treatment CTC samples for percentage of patients with vimþ CTCs (23.2% baseline vs 17.3% post-treatment, P ¼ 0.373) (supplementary Table S2 , available at Annals of Oncology online), percentage of patients with dynamic change of vimþ and vimnegative CTCs during treatment (17.6% stability/increase for vimþ patients vs 13.5% for vim-negative, P ¼ 0.696) (supplementary Table S3 , available at Annals of Oncology online), and ratio of vimþ:total CTCs (median 0.118 at baseline vs 0.167 ontreatment; P ¼ 0.645) (supplementary Figure S3 , available at Annals of Oncology online).
CTCs according to NSCLC molecular subgroups
Of the 125 patients analyzed with CellSearch at baseline, 104 had their tumors tested for genetic modifications and 67 of these cancers (64.4%) were found to harbor at least one 'actionable' aberration. 22/90 patients (24.4%) had tumors which were KRASmutated, 21/94 (22.3%) were EGFR-mutated, and 13/90 (14.4%) ALK-rearranged. Figure 4A and B shows bar plots of total CTC numbers and vimþ CTC proportions according to molecular subgroups, while Table 3 compares relative numbers of total CTCþ and vim CTCþ patients in each subgroup. On examination of the KRAS Figure 4C ). Only two KRAS-mutant patients harbored vimþ CTCs, and on review of their medical records it was noted that neither of these patients had a histological diagnosis of adenocarcinoma (1 squamous Figure 4D ).
For the ALK-assessed subgroup, a trend towards diminished patient numbers with total CTCs in ALK-rearranged cancer was supported by a significant reduction in total CTC numbers overall (rearranged vs WT: 2/13 total CTCþ patients vs 31/77 total CTCþ patients, 15.4% vs 40.3%, P ¼ 0.122; mean 1.69 vs 5.82 total CTCs, P ¼ 0.029) ( Table 3 , Figure 4E ). Both vim CTCþ ALK-rearranged patients were noted to have high proportions of vimþ CTCs relative to total CTCs ( Figure 4B ).
Discussion
Here we report a prognostic validation of CTC estimation by CellSearch in advanced/metastatic NSCLC, as well as offering a clinical insight into their epithelial-mesenchymal properties according to analysis of the whole NSCLC population and its genetic subtypes. In line with what has been previously reported, we initially validated the prognostic value of !5 total CTCs at baseline through analysis of OS. The presence or absence of CTCs with EMT characteristics across the whole cohort conferred no additional prognostic significance when total CTCþ patients were subdivided into vimþ CTC and vim-CTC cohorts. However, the presence of vimþ CTCs was heterogeneous within the three main NSCLC genetic subgroups studied in our report: EGFR-mutation, ALK rearrangement and KRAS-mutation. A significantly high number of vimþ patients and vimþ CTC numbers in EGFR-mutant disease contrasted with a total loss of vimþ CTC patients and vimþ CTCs in KRAS-mutant adenocarcinoma. For ALK-rearranged patients there were fewer total CTCs with no difference in vimþ CTCs. We validated the prognostic cutoff of !5 total CTCs previously identified using CellSearch, using both univariate and multivariate testing of OS, albeit with a higher number of patients with total CTC-positivity (40Á8%) compared to that which was reported previously [4] . To the best of our knowledge, this is the largest clinical study of CTCs analyzed by CellSearch in advanced NSCLC patients to date. The importance of offering this validation was to follow predictive/prognostic biomarker guidelines such as REMARK and the Cancer Research UK biomarker roadmap, prospectively confirming the relationship between CTCs and NSCLC outcomes to pave the way for a clinical trial where CTCs can be used to define randomization [19, 20] . Given the association of EGFR mutation in this study with high numbers of total CTCþ patients, it is possible that the relative enrichment of EGFR-positive patients (21/94 patients, 22.3%) in our study has contributed to this increased number of total CTCþ patients overall. A European multi-centre pooled analysis of NSCLC CTCs by CellSearch has now completed recruitment and should facilitate a final focus on clinical validity by providing an answer to this question, as well as offering a rounded picture of the percentage of patients with total CTC-positivity in advanced disease.
EMT has previously been associated with tumor invasiveness, chemoresistance, and poor clinical outcomes [9] . For vimentin assessment here, an initial biological selection during CellSearch should be noted: it will only test for vimentin after patient CTCs have been initially isolated using EPCAM-coated ferromagnetic beads, an epithelial-antibody based selection. A fully representative picture of mesenchymal or EMT CTCs is impaired as a consequence. CellSearch was selected for use due to its advanced level of assay and biological validity: its ability to prognosticate has been tested extensively in the clinic and published in a number of cancers, with FDA-approval granted for advanced breast, colorectal, and prostate cancers, and its use is consistent and reproducible across all patient cohorts for the purposes of survival analyses and correlation with clinical/molecular markers [1] . A more biological picture of mesenchymal CTCs or CTCs in EMT has been exploited by a number of other CTC isolation techniques that have not yet reached the same level of assay validity [10] [11] [12] [13] [14] .
Across NSCLC overall, vimentin presence did not confer an additional survival difference in those patients that were total CTC-positive, although this level of survival analysis with relatively small patient numbers does not take into account that NSCLC is a diagnosis of histological exclusion which covers a myriad of different genetic and biological pathological processes [21] . With more detailed analysis, evidence of increased total and vimþ CTCs was apparent in EGFR-mutant patients, as well as a total absence of vimþ CTCs in KRAS-mutated adenocarcinomas. The presence of differential vimþ CTC profiles amongst different genetic and histological subgroups of NSCLC suggests that each subgroup may display a different level of CTC dynamic plasticity. The higher number of total CTCþ patients suggests that EGFR-mutant NSCLC will also be of particular interest for design of CTC-based clinical trials: this result is consistent with two other reports that used alternative methods of CTC isolation to characterize small numbers of patients with EGFR-mutated NSCLC [22, 23] .
The network of French molecular platforms offer a unique clinical infrastructure where molecular profiling of NSCLC patients for key modifications such as EGFR, KRAS, and ALK has been performed routinely for a number of years, creating opportunities for translational research such as the findings described in this report [17] . The association between EGFR mutation and vimþ CTCs in our study is a result that would have been expected in patients developing acquired resistance to EGFR inhibition, but is perhaps more surprising in the context of systemic treatment-naive disease. Biopsy and cell line studies of EGFRmutant disease have however consistently shown the presence of vimentin expression before the onset of treatment resistance, including one landmark study which detailed EMT as a mechanism of resistance in EGFR-mutant patients [24] [25] [26] [27] . In this study, we noted vimentin-positivity in the baseline CTCs of 26% of EGFR-mutated patients. These findings reinforce a hypothesis that the development of EMT-mediated resistance in cancers treated with EGFR inhibitors is conferred by an increase in EMT markers, perhaps with an on-off threshold effect, rather than outright de novo induction. For KRAS mutation, the absence of vimþ CTCs in adenocarcinoma is consistent with a total lack of vimentin expression observed in tumors resected from a transgenic mouse model of KRAS-driven lung cancer, although this study cannot exclude the possibility that pure mesenchymal CTCs missed by CellSearch could hold importance in this molecular subtype [28] . Our previous report showing that ALK-rearranged CTCs exhibit a complete loss of epithelial marker expression and potentially a fully mesenchymal phenotype, expressing vimentin and N-cadherin, is consistent with the low level of total CTCs in patients with ALK-rearranged tumors observed in this study [13] .
In conclusion, we validate a prognostic survival difference using a cutoff of !5 total CTCs isolated by CellSearch in the largest cohort of NSCLC patients reported so far. For the first time, we show that differential EMT characteristics and total CTC profiles can be observed according to different genetic subtypes of NSCLC. In a cancer where small samples and poor biopsy quality can often slow its molecularly driven clinical development, future studies can focus on examining how the clinical utility of CTCs can be best exploited in genetic subtypes of NSCLC.
